The Cardio-Kidney Patient: Epidemiology, Clinical Characteristics and Therapy.

"Disclosures K. Schuett has received personal fees from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Lilly, Merck Sharp and Dohme, Novo Nordisk, Novartis, and OmniaMed and served as a consultant for Amgen, AstraZeneca, Bayer, and Boehringer Ingelheim. N. Marx has received support for clinical trial leadership from Boehringer Ingelheim and Novo Nordisk; served as a consultant to Boehringer Ingelheim, Merck, Novo Nordisk, AstraZeneca, and Bristol Myers Squibb; received grant support from Boehringer Ingelheim, Merck, and Novo Nordisk; and served as a speaker for Boehringer Ingelheim, Merck, Novo Nordisk, Lilly, BMS, and AstraZeneca. M. Lehrke received grants and personal fees from Boehringer Ingelheim, MSD, and Novo Nordisk and personal fees from Amgen, Sanofi, AstraZeneca, Bayer, Lilly, Daiichi Sankyo, Novarits, Amylin, MSD, Novo Nordisk, and Abiomed."

"Sources of Funding K. Schuett is supported by Deutsche Forschungsgemeinschaft (German Research Foundation; TRR 219; project ID 322900939 [C07]). N. Marx is supported by Deutsche Forschungsgemeinschaft (German Research Foundation; TRR 219; project ID 322900939 [M03 and M05]). M. Lehrke is supported by Deutsche Forschungsgemeinschaft (German Research Foundation; TRR 219; project ID 322900939 [M03]; LE1350/9-1) and Deutsche Herzstiftung."